 |
268 Diseases |  |
30 Trials |
|
30 Trials |  |
2139 News |  |
| «12...26272829303132333435363738» |
- Cytovene (ganciclovir) / Roche
New P4 trial: Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis (clinicaltrials.gov) - Oct 25, 2016
P4, N=25, Recruiting, Sponsor: Singapore National Eye Centre
- |||||||||| Livtencity (maribavir) / Takeda, GSK
New P3 trial: SOLSTICE: Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir (clinicaltrials.gov) - Oct 13, 2016
P3, N=351, Not yet recruiting, Sponsor: Shire
- ||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment closed: GRAIL: Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure (clinicaltrials.gov) - Jul 7, 2016
P2, N=160, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting
- Cytovene (ganciclovir) / Roche
Trial primary completion date: Gan Premie: Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=32, Recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> Jul 2018
- | Cytovene (ganciclovir) / Roche, Vistide (cidofovir) / Gilead
Trial completion: Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) (clinicaltrials.gov) - Mar 12, 2016
P3, N=61, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Trial primary completion date: Jul 2016 --> Jul 2018 No longer recruiting --> Completed
- | Cytovene (ganciclovir) / Roche
Trial completion: Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma (clinicaltrials.gov) - Feb 1, 2016
P2, N=0, Completed, Sponsor: AIDS Malignancy Consortium
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
Trial completion, Trial primary completion date: A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation (clinicaltrials.gov) - Jan 4, 2016
P3, N=301, Completed, Sponsor: Hoffmann-La Roche
No longer recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Oct 2015
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment change: Q-CMV: Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=50, Recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Oct 2015 N=100 --> 50
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial completion, Enrollment change: Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. (clinicaltrials.gov) - Mar 27, 2015
P4, N=60, Completed, Sponsor: Nuria Lloberas
N=100 --> 50 Recruiting --> Completed | N=50 --> 60
- || Livtencity (maribavir) / Takeda, GSK
Trial primary completion date: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients (clinicaltrials.gov) - Mar 10, 2015
P2, N=120, Completed, Sponsor: Shire
Recruiting --> Completed | N=50 --> 60 Trial primary completion date: Sep 2014 --> Dec 2014
- |||| Livtencity (maribavir) / Takeda, GSK
Trial completion: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients (clinicaltrials.gov) - Mar 7, 2015
P2, N=120, Completed, Sponsor: Shire
Trial primary completion date: Sep 2014 --> Dec 2014 Active, not recruiting --> Completed
- Cytovene (ganciclovir) / Roche
Clinical: Q-CMV: Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients (clinicaltrials.gov) - Feb 26, 2015
P=N/A, N=100, Recruiting, Sponsor: University Health Network, Toronto
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial completion, Trial primary completion date, IO biomarker: Cytomegalovirus Control in Critical Care (clinicaltrials.gov) - Jan 12, 2015
P2, N=124, Completed, Sponsor: University Hospital Birmingham NHS Foundation Trust
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Feb 2013 --> Jan 2014
- darTregs / National Institute of Allergy and Infectious Diseases
Enrollment open, Trial initiation date: deLTa: Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (clinicaltrials.gov) - Dec 19, 2014
P1, N=24, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Feb 2013 --> Jan 2014 Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014
- || Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial primary completion date: GRAIL: Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure (clinicaltrials.gov) - Sep 28, 2014
P2, N=160, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014 Trial primary completion date: Aug 2014 --> Aug 2015
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial completion, Trial primary completion date: Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) (clinicaltrials.gov) - Sep 5, 2014
P4, N=165, Completed, Sponsor: University College, London
Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Completed | Trial primary completion date: Feb 2011 --> Dec 2011
- | Cytovene (ganciclovir) / Roche, ProstAtak (aglatimagene besadenovec) / Candel Therap
New P2 trial, Metastases: Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 30, 2014
P2, N=81, Completed, Sponsor: Huazhong University of Science and Technology
- darTregs / National Institute of Allergy and Infectious Diseases
New P1 trial: deLTa: Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (clinicaltrials.gov) - Jul 14, 2014
P1, N=24, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | Cytovene (ganciclovir) / Roche, Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Islet Transplantation for Type 1 Diabetes (clinicaltrials.gov) - Jun 8, 2014
P2, N=36, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Feb 2011 --> Dec 2011 Active, not recruiting --> Completed
- | Cytovene (ganciclovir) / Roche
New P4 trial: PTH - Preemptive Treatment for Herpesviridae (clinicaltrials.gov) - May 29, 2014
P4, N=480, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
- Cytovene (ganciclovir) / Roche
Enrollment change: Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant (clinicaltrials.gov) - Mar 26, 2014
P2, N=61, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=24 --> 61
- ||| Livtencity (maribavir) / Takeda, GSK
Enrollment closed: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients (clinicaltrials.gov) - Mar 23, 2014
P2, N=120, Active, not recruiting, Sponsor: Shire
N=24 --> 61 Recruiting --> Active, not recruiting
- | Cytovene (ganciclovir) / Roche
Trial completion: Neonatal CMV-Ganciclovir Follow-up Study (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=8, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
Trial completion: Valganciclovir in Congenital CMV Infants (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
Trial completion: Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation (clinicaltrials.gov) - Feb 19, 2014
P3, N=184, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cytovene (ganciclovir) / Roche
Trial completion: A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. (clinicaltrials.gov) - Feb 19, 2014
P3, N=130, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- |||| Cytovene (ganciclovir) / Roche
Trial completion: The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV (clinicaltrials.gov) - Feb 19, 2014
P2, N=850, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Cytovene (ganciclovir) / Roche
Trial completion, Gene therapy: Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cytovene (ganciclovir) / Roche
Trial completion: A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment change: Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=153, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=300 --> 153
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial completion: Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=153, Completed, Sponsor: City of Hope Medical Center
N=300 --> 153 Suspended --> Completed
- Cytovene (ganciclovir) / Roche
Enrollment open: Gan Premie: Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection (clinicaltrials.gov) - Nov 16, 2013
P=N/A, N=32, Recruiting, Sponsor: University of Alabama at Birmingham
Suspended --> Completed Not yet recruiting --> Recruiting
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial termination: Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Jul 21, 2013
P3, N=39, Terminated, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Completed --> Terminated; Due to low accrual
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial initiation date: A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls (clinicaltrials.gov) - Apr 7, 2013
P=N/A, N=37, Recruiting, Sponsor: Hoffmann-La Roche
Completed --> Terminated; Due to low accrual Initiation date: Jul 2011 --> Jan 2012
- Cytovene (ganciclovir) / Roche
Trial completion, Viral vector: A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers (clinicaltrials.gov) - Feb 10, 2013
P1, N=11, Completed, Sponsor: University of Alabama at Birmingham
Initiation date: Jul 2011 --> Jan 2012 Active, not recruiting --> Completed
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial initiation date: Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Jan 17, 2013
P3, N=39, Terminated, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Initiation date: Mar 2004 --> Jun 2004
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment change: Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Jan 17, 2013
P3, N=39, Terminated, Sponsor: Washington University School of Medicine
Initiation date: Mar 2004 --> Jun 2004 N=120 --> 39
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial termination: CONVINCE: Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Dec 6, 2012
P3, N=212, Terminated, Sponsor: Pierrel Research Europe GmbH
N=120 --> 39 Recruiting --> Terminated
- | Cytovene (ganciclovir) / Roche, Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Pediatric Kidney Transplant Without Calcineurin Inhibitors (clinicaltrials.gov) - Oct 30, 2012
P=N/A, N=35, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Terminated Active, not recruiting --> Completed
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment change: A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls (clinicaltrials.gov) - Sep 18, 2012
P=N/A, N=37, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=3737 --> 37
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Clinical: A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=37, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| Livtencity (maribavir) / Takeda, GSK
New P2 trial: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients (clinicaltrials.gov) - Jun 3, 2012
P2, N=120, Active, not recruiting, Sponsor: Shire
- Cytovene (ganciclovir) / Roche
Trial withdrawal: A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease. (clinicaltrials.gov) - May 28, 2012
P1/2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=3737 --> 37 Terminated --> Withdrawn
- Cytovene (ganciclovir) / Roche
Trial withdrawal: A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir (clinicaltrials.gov) - May 28, 2012
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Terminated --> Withdrawn Terminated --> Withdrawn
- Cytovene (ganciclovir) / Roche
Enrollment change: A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease. (clinicaltrials.gov) - May 28, 2012
P1/2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Terminated --> Withdrawn N=30 --> 0
- Cytovene (ganciclovir) / Roche
Enrollment change: A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir (clinicaltrials.gov) - May 28, 2012
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=30 --> 0 N=168 --> 0
- Cytovene (ganciclovir) / Roche
Enrollment change, Viral vector: A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers (clinicaltrials.gov) - May 8, 2012
P1, N=11, Completed, Sponsor: University of Alabama at Birmingham
N=168 --> 0 N=14 --> 11
- Cytovene (ganciclovir) / Roche
Trial completion: A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease (clinicaltrials.gov) - Mar 29, 2012
P1, N=32, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=14 --> 11 Active, not recruiting --> Completed
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment open: Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. (clinicaltrials.gov) - Mar 19, 2012
P4, N=50, Recruiting, Sponsor: Nuria Lloberas
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment open, IO biomarker: Cytomegalovirus Control in Critical Care (clinicaltrials.gov) - Feb 4, 2012
P2, N=141, Recruiting, Sponsor: University Hospital Birmingham NHS Foundation Trust
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting